PDL BioPharma, Inc. (PDLI): Analyzing Basic Trading Data

In the past 52-week period, shares of PDL BioPharma, Inc. (NASDAQ:PDLI) have moved within the range of $1.93 to $3.55. On the stock’s most recent trading day, the company’s shares ended the regular session at $2.88, which is 18.87% higher than its 52-week high.

PDL BioPharma, Inc. (PDLI) has demonstrated a 20-day simple moving average (SMA) of -1.94%, and a 50-day SMA of -9.12%. This public company’s current market capitalization stands at $453.69 million.

Analyzing Consensus Estimates, Sales Revenue and Net Income

Measuring Wall Street analysts’ average enthusiasm for a specific stock is critical when considering a potential investment. According to the latest data, the consensus recommendation for PDL BioPharma, Inc. (PDLI) is Outperform.

Publicly-traded companies normally report earnings and revenue figures that are either above or below the average Wall Street projection. In the most recent quarterly financial report, for the quarter ending Sep. 2017, PDL BioPharma, Inc. (PDLI) delivered a 1.44% surprise with its net revenue. Sales reached $0.06 billion during the three-month period, compared to the average analyst estimate of $0.06 billion.

Ownership at PDL BioPharma, Inc. (PDLI), According to Most Recent SEC Filings

We can gain important insight by taking a look at institutional ownership, as detailed in public companies’ latest 13F filings. PDL BioPharma, Inc. (PDLI) has 0 billion shares outstanding currently, 90.26% of which belong to institutional investors. Those institutional holdings amount to $0.41 billion.

Additionally, according to the most recent 13F filing from PDL BioPharma, Inc. (PDLI), there were 30 new positions totaling 2,055,263 shares of the company’s stock. There were 13 sold out positions, on the other hand, totaling 636,748 shares.

Short, Medium and Long Term Indicators

Analyzing the average trade volume of a publicly-traded company’s stock – in the short, medium and long terms – is helpful for gaining insight into trading activity and general investor sentiment. PDL BioPharma, Inc. (PDLI) has had a 20-day average volume of 1,527,815 shares, with an average of 60% of short term indicators pointed at Sell.

The stock’s 50-day average volume has been 1,772,588 shares, with an average of 25% of medium term indicators pointing toward Sell. Finally, its 100-day average volume is 1,853,417 shares with 0% of long-term indicators pointing to Hold.